Papers/PMID:41515249
Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.
Nutrients2025The record
7 findings drawn from this paper, on 1 compound across 7 endpoints, 1 of them null.
What it reported
How to read these marksWhat moved
6 findings
melatonin — increases total antioxidant capacity
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Findingreplicated ×1“The meta-analysis indicated that melatonin supplementation considerably lowered serum MDA levels (WMD: −1.54 μmol/L, 95% CI: −2.07, −1.01) and markedly increased serum TAC levels (WMD: 0.15 mmol/L, 95% CI: 0.08, 0.22) in the melatonin-treated group versus the untreated group.”
Quoted verbatim from Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.. - Study
- meta-analysis
- Population
- adults, pooled across 63 RCTs of melatonin supplementation across mixed clinical populations (including metabolic syndrome, chronic kidney disease, PCOS, COVID-19, multiple sclerosis, type 2 diabetes, and other conditions)
Effect 0.15 mean difference, 95% CI 0.08 to 0.22
Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.2025PMID:41515249
melatonin — decreases fasting blood glucose
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Findingreplicated ×1“The pooled analysis displayed that melatonin supplementation substantially lowered serum FBG levels in the melatonin group compared with the placebo group (WMD: −11.63 mg/dL, 95% CI: −19.16, −4.10).”
Quoted verbatim from Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.. - Study
- meta-analysis
- Dose
- 0.3-100 mg/day oral
- Population
- adults in 63 RCTs of melatonin supplementation vs placebo across mixed clinical populations
Effect -11.63 mean difference, 95% CI -19.16 to -4.1
Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.2025PMID:41515249
melatonin — decreases malondialdehyde (circulating)
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Findingreplicated ×1“The meta-analysis indicated that melatonin supplementation considerably lowered serum MDA levels (WMD: −1.54 μmol/L, 95% CI: −2.07, −1.01) and markedly increased serum TAC levels (WMD: 0.15 mmol/L, 95% CI: 0.08, 0.22) in the melatonin-treated group versus the untreated group.”
Quoted verbatim from Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.. - Study
- meta-analysis
- Dose
- 0.3-100 mg/day oral
- Population
- adults in 63 RCTs of melatonin supplementation vs placebo across mixed clinical populations
Effect -1.54 mean difference, 95% CI -2.07 to -1.01
Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.2025PMID:41515249
melatonin — decreases total cholesterol (TC)
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Finding“The meta-analysis indicated that melatonin supplementation significantly reduced serum TC (WMD: −6.97 mg/dL, 95% CI: −12.20, −1.74) and LDL-C levels (WMD: −6.28 mg/dL, 95% CI: −10.53, −2.03) in the melatonin group compared with the control group.”
Quoted verbatim from Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.. - Study
- meta-analysis
- Dose
- 0.3-100 mg/day oral
- Population
- adults in 63 RCTs of melatonin supplementation vs placebo across mixed clinical populations
Effect -6.97 mean difference, 95% CI -12.2 to -1.74
Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.2025PMID:41515249
melatonin — increases HDL cholesterol
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Finding“HDL-C levels were substantially increased (WMD: 2.04 mg/dL, 95% CI: 0.50, 3.57) following melatonin supplementation.”
Quoted verbatim from Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.. - Study
- meta-analysis
- Dose
- 0.3-100 mg/day oral
- Population
- adults in 63 RCTs of melatonin supplementation vs placebo across mixed clinical populations
Effect 2.04 mean difference, 95% CI 0.5 to 3.57
Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.2025PMID:41515249
melatonin — decreases LDL cholesterol
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Finding“The meta-analysis indicated that melatonin supplementation significantly reduced serum TC (WMD: −6.97 mg/dL, 95% CI: −12.20, −1.74) and LDL-C levels (WMD: −6.28 mg/dL, 95% CI: −10.53, −2.03) in the melatonin group compared with the control group.”
Quoted verbatim from Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.. - Study
- meta-analysis
- Dose
- 0.3-100 mg/day oral
- Population
- adults in 63 RCTs of melatonin supplementation vs placebo across mixed clinical populations
Effect -6.28 mean difference, 95% CI -10.53 to -2.03
Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.2025PMID:41515249
What did not
1 finding
melatonin — no detected effect on HOMA-IR
LikelyGrade B, Likely. Human evidence, limited replication or design limits.FindingNull result“No significant effects of melatonin were found on HOMA-IR (WMD: 0.15, 95% CI: −0.18, 0.48), serum FI levels (WMD: 0.49 µIU/mL, 95% CI: −1.08, 2.05), or HbA1c (WMD: −0.22%, 95% CI: −0.66, 0.21).”
Quoted verbatim from Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.. - Study
- meta-analysis
- Population
- adults, pooled across 63 RCTs of melatonin supplementation across mixed clinical populations (including metabolic syndrome, chronic kidney disease, PCOS, COVID-19, multiple sclerosis, type 2 diabetes, and other conditions)
Effect 0.15 mean difference, 95% CI -0.18 to 0.48
Comprehensive Effects of Melatonin Supplementation on Cardiometabolic Risk Factors: A Systematic Review and Dose-Response Meta-Analysis.2025PMID:41515249